CITIUS ONCOLOGY, INC. CTOR

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

is a biopharmaceutical company focused on developing and commercializing innovative targeted oncology therapies. The Company's strategy

centers on achieving a market leading position by advancing innovative therapies with reduced development and clinical risks, and competitive

advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved

drugs with substantial existing safety and efficacy data or expanded indications for approved therapies.

Last close 0.58 2026-10-23
Market cap $53.9M 2026-06-30 share count
52-week range 0.49 - 1.93

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-0.34

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021
R&D $6.4M$4.9M$4.2M——
SG&A $8.8M$8.1M$5.9M$138.1K—
Total operating expenses $23.5M$20.6M$12.1M——
Operating income -$23.5M-$20.6M-$1.0M-$138.1K—
Interest expense $218.0K————
Pre-tax income -$23.7M-$20.6M-$12.1M——
Income tax $1.1M$576.0K$576.0K——
Net income -$24.8M-$21.1M-$12.7M$380.8K—
EPS, basic -0.34-0.31-0.190.12—
EPS, diluted -0.34-0.31-0.190.12—
Shares, diluted (wtd. avg.) 73.3M68.1M67.5M1.3M—

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021
Cash and equivalents $3.9M$112———
Inventory $22.3M$8.3M———
Total current assets $27.5M$11.0M$7.7M$377.3K$126.4K
Total assets $100.9M$84.4M$47.7M$68.2M$126.4K
Accounts payable $13.2M$3.7M$1.3M——
Total current liabilities $49.5M$32.7M$21.0M$31.8K$136.5K
Total liabilities $56.1M$38.2M$22.2M——
Retained earnings -$64.0M-$39.3M-$18.1M$345.3K-$10.1K
Total equity $44.9M$46.1M$25.5M$36.3M-$10.1K

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021
Operating cash flow -$5.5M$126.4K-$601.3K-$48.0K—
Stock-based compensation $8.3M$7.5M$2.0M——
Investing cash flow -$5.8M-$5.0M-$1.3M-$67.3M—
Financing cash flow $15.2M$4.9M$1.7M$67.7M—

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-25-125331.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -30M -20M -10M 0 10M Net income, FY2022: 380.8K Net income, FY2023: -12.7M Net income, FY2024: -21.1M Net income, FY2025: -24.8M FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2021FY2022FY2023FY2024FY2025
Revenue — — — — —
Gross profit — — — — —
Net income — $380.8K -$12.7M -$21.1M -$24.8M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Other event Item 8.01
  • Results announced Item 2.02
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
  • Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
  • Other event Item 8.01
  • Other event Item 8.01
  • Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
  • Other event Item 8.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%